Table 3.
Summary of outcomes from the five clinical trials included in the review.
| Publication | Location | Intervention (N enrolled) | Comparatora (N enrolled) | Atovaquone-Proguanil OR Proguanil-containing regimen (n/N) | Comparator (n/N) a | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||
| Miscarriage | Still-birth | Early Death | Cong. Anomaly | Miscarriage | Still-birth | Early Death | Cong. Anomaly | ||||
|
| |||||||||||
| McGready et al, 2005 [18] | Thailand | Atovaquone-proguanil (N = 39) | Quinine (N = 42) | 0/34 | 1/34 | NA | 2/34 | 0/38 | 0/38 | NA | 1/38 |
| Mutabingwa et al, 1993 [19] | Tanzania | Proguanil alone (N = 124) or proguanil plus chloroquine (N = 90) | Chloroquine (N = 155) | 2/214 | 1/214 | NA | NA | 0/113 | 0/113 | NA | NA |
| Fleming, A., 1990 [20] | Nigeria | Proguanil (N = 160) | Placebo(N = 40) | 6/134 | NA | NA | NA | 0/32 | NA | NA | NA |
| Kasso et al, 2012 [21] | Nigeria | Proguanil (N = 175) | Sulphadoxine-pyrimethamine (N = 175) | 0/139 | 0/139 | 0/139 | 0/139 | 0/142 | 0/142 | 0/142 | 0/142 |
| Mutabingwa et al, 2009 [22] | Tanzania | Chlorproguanil-Dapsone (N = 81) | Sulphadoxine-Pyrimethamine (N = 28) SP + amodiaquine (N = 80) Artesunate + Amodiaquine (N = 83) |
0/74 | 1/74 | 5/74 | 13/74 | 0/26 0/75 0/79 |
1/26 1/75 4/79 |
1/26 2/75 0/79 |
6/26 14/75 15/79 |
a
The comparator outcomes correspond to the drug regimen defined in the first comparator column.